Sivik Global Healthcare’s Neurocrine Biosciences NBIX Stock Holding History

Sivik Global Healthcare’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22,500	Closed	-$2.11M	–	49
2022 Q1	$2.11M	Buy	+22,500	New	+$1.91M	0.87%	46
2019 Q3	–	Sell	-40,000	Closed	-$3.38M	–	53
2019 Q2	$3.38M	Buy	+40,000	New	+$3.28M	0.82%	35
2018 Q2	–	Sell	-30,000	Closed	-$2.49M	–	69
2018 Q1	$2.49M	Sell	30,000 -5,000	-14%	-$422K	1.16%	35
2017 Q4	$2.72M	Buy	35,000 +5,000	+17%	+$341K	1.01%	48
2017 Q3	$1.84M	Buy	30,000 +10,000	+50%	+$528K	0.63%	59
2017 Q2	$920K	Sell	20,000 -5,000	-20%	-$243K	0.34%	64
2017 Q1	$1.08M	Hold	25,000	–	–	0.5%	56
2016 Q4	$968K	Buy	25,000 +9,400	+60%	+$426K	0.46%	49
2016 Q3	$790K	Buy	+15,600	New	+$777K	0.4%	46

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Sivik Global Healthcare's NBIX Position: Q2 2022 in Review

Sivik Global Healthcare sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 22,500 shares — an estimated $2.11M sold.

Sivik Global Healthcare first reported a position in NBIX in Q3 2016 and held it in 9 quarters. The position peaked at $3.38M in Q2 2019. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

Sivik Global Healthcare reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
Sivik Global Healthcare sold 22,500 Neurocrine Biosciences shares in Q2 2022, an estimated $2.11M.
Sivik Global Healthcare first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 9 quarters.
Sivik Global Healthcare's Neurocrine Biosciences position peaked at $3.38M in Q2 2019.
438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Sivik Global Healthcare's 13F filing for Q2 2022, filed 10 Aug 2022.